Kinase-targeted cancer therapies: progress, challenges and future directions

Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil

(2018) H. Kittler et al.   BRITISH JOURNAL OF DERMATOLOGY

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT

(2017) Dan Sandberg et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Determining Cysteines Available for Covalent Inhibition Across the Human Kinome

(2017) Zheng Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Anti-Metastatic and Anti-Invasion Effects of a Specific Anti-MUC18 scFv Antibody on Breast Cancer Cells

(2016) Mozafar Mohammadi et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition

(2016) Dohyun Park et al.   Scientific Reports

Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers

(2015) Sameh Mikhail et al.   AMERICAN JOURNAL OF PATHOLOGY

Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer

(2015) Mariya O. Krisenko et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The ABC of protein kinase conformations

(2015) Henrik Möbitz   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

(2015) Suleiman Massarweh et al.   BREAST CANCER RESEARCH AND TREATMENT

Ten things you should know about protein kinases: IUPHAR Review 14

(2015) Doriano Fabbro et al.   BRITISH JOURNAL OF PHARMACOLOGY

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

(2015) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

The evolving field of kinase inhibitors in thyroid cancer

(2015) V. Marotta et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2015) Bin-Chi Liao et al.   CURRENT OPINION IN ONCOLOGY

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

(2015) A. Scholtens et al.   EUROPEAN JOURNAL OF CANCER

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

(2015) Daniel Morgensztern et al.   Journal of Thoracic Oncology

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer

(2015) Tetsutaro Hayashi et al.   JOURNAL OF UROLOGY

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers

(2015) Vipin Yadav et al.   PHARMACOLOGY & THERAPEUTICS

Targeting PI3 kinase in cancer

(2015) Todd M. Bauer et al.   PHARMACOLOGY & THERAPEUTICS

Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort

(2015) Cecile N. Chougnet et al.   THYROID

Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data

(2015) Omar Abdel-Rahman et al.   TUMOR BIOLOGY

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

(2015) A Eriksson et al.   Blood Cancer Journal

Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors

(2015) Philippe L. Bedard et al.   CANCER RESEARCH

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

(2014) Sadhna R. Vora et al.   CANCER CELL

Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway

(2014) Arif Khan et al.   Cancer Epidemiology

Recently targeted kinases and their inhibitors—the path to clinical trials

(2014) Stefan Knapp et al.   CURRENT OPINION IN PHARMACOLOGY

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial

(2014) Stéphane Haïk et al.   LANCET NEUROLOGY

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein

(2014) S Shukla et al.   LEUKEMIA

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

(2014) P. Yu et al.   MOLECULAR CANCER THERAPEUTICS

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncology Drug Discovery: Planning a Turnaround

(2014) C. Toniatti et al.   Cancer Discovery

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma

(2013) Arati Sharma et al.   AMERICAN JOURNAL OF PATHOLOGY

Targeted Therapy for Breast Cancer

(2013) Ali Mohamed et al.   AMERICAN JOURNAL OF PATHOLOGY

Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design

(2013) Javier Blanc et al.   Anti-Cancer Agents in Medicinal Chemistry

Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer

(2013) K. Kavitha et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Cyclin-Dependent Kinase Modulators and Cancer Therapy

(2013) Marialucia Gallorini et al.   BIODRUGS

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Developing Irreversible Inhibitors of the Protein Kinase Cysteinome

(2013) Qingsong Liu et al.   CHEMISTRY & BIOLOGY

The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China

(2013) You-ru Liu et al.   Clinical Respiratory Journal

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

Differential Effects of Dehydroepiandrosterone and Testosterone in Prostate and Colon Cancer Cell Apoptosis: The Role of Nerve Growth Factor (NGF) Receptors

(2013) Vasileia Anagnostopoulou et al.   ENDOCRINOLOGY

Targeted therapy with kinase inhibitors in aggressive endocrine tumors

(2013) Vincenzo Marotta et al.   EXPERT OPINION ON PHARMACOTHERAPY

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Aurora Kinase Inhibition As an Anticancer Strategy

(2013) John F. Hilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells

(2013) Chun-Yin Huang et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology

(2013) S Ogino et al.   ONCOGENE

Disrupting the Scaffold to Improve Focal Adhesion Kinase-Targeted Cancer Therapeutics

(2013) W. G. Cance et al.   Science Signaling

The JAK2/STAT3 and mitochondrial pathways are essential for quercetin nanoliposome-induced C6 glioma cell death

(2013) G Wang et al.   Cell Death & Disease

Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management

(2012) Vaqar Mustafa Adhami et al.   BIOCHEMICAL PHARMACOLOGY

Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival

(2012) Keng Gat Lim et al.   BRITISH JOURNAL OF PHARMACOLOGY

Abstract 5445: Polyphenolic phytochemical curcumin suppresses HER-2 protein phosphorylation and gene expression in breast cancer cells

(2012) T. J. Thomas et al.   CANCER RESEARCH

Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells

(2012) Gayathri Chadalapaka et al.   CARCINOGENESIS

Protein Kinase C-β Contributes to Impaired Endothelial Insulin Signaling in Humans With Diabetes Mellitus

(2012) Corey E. Tabit et al.   CIRCULATION

New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors

(2012) Vandana Lamba et al.   CURRENT PHARMACEUTICAL DESIGN

The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells

(2012) Fang Xie et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220

(2012) D. Pauwels et al.   HAEMATOLOGICA

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

(2012) Tjeerd Barf et al.   JOURNAL OF MEDICINAL CHEMISTRY

Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression

(2012) XIAO-DONG SUN et al.   Molecular Medicine Reports

EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol

(2012) Kang Jin Jeong et al.   Molecular Oncology

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

(2012) V Chell et al.   ONCOGENE

Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway

(2012) Sandeep Sheth et al.   PLoS One

Approaches to discover non-ATP site kinase inhibitors

(2012) Lori Krim Gavrin et al.   MedChemComm

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling

(2011) Arvin C. Dar et al.   Annual Review of Biochemistry

Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor

(2011) Glenn S. Van Aller et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

(2011) Qing Dong et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Protein kinase biochemistry and drug discovery

(2011) Phillip A. Schwartz et al.   BIOORGANIC CHEMISTRY

The rise and fall of gatekeeper mutations? TheBCR-ABL1T315I paradigm

(2011) Don L. Gibbons et al.   CANCER

Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model

(2011) Lu-Xia Chen et al.   CANCER BIOLOGY & THERAPY

Irreversible Protein Kinase Inhibitors

(2011) L. Garuti et al.   CURRENT MEDICINAL CHEMISTRY

Apoptotic Effects of Genistein, Biochanin-A and Apigenin on LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition of Polo-like Kinase-1

(2011) Young Jin Seo et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors

(2011) Emeline Leproult et al.   JOURNAL OF MEDICINAL CHEMISTRY

Quercetin-induced Growth Inhibition in Human Bladder Cancer Cells Is Associated with an Increase in Ca2+-activated K+Channels

(2011) Yangmi Kim et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

(2011) G Metzgeroth et al.   LEUKEMIA

EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells

(2011) Shu-Jun Chen et al.   MOLECULAR BIOLOGY REPORTS

Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells

(2011) Jia-Ching Wu et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

The resurgence of covalent drugs

(2011) Juswinder Singh et al.   NATURE REVIEWS DRUG DISCOVERY

Raf kinases in cancer–roles and therapeutic opportunities

(2011) G Maurer et al.   ONCOGENE

Drug discovery and the human kinome: Recent trends

(2011) Richard Eglen et al.   PHARMACOLOGY & THERAPEUTICS

Overexpression of Active Aurora-C Kinase Results in Cell Transformation and Tumour Formation

(2011) Jabbar Khan et al.   PLoS One

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site

(2010) Doriano Fabbro et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Development of curcumin as an epigenetic agent

(2010) Siqing Fu et al.   CANCER

Luteolin Inhibits Protein Kinase C  and c-Src Activities and UVB-Induced Skin Cancer

(2010) S. Byun et al.   CANCER RESEARCH

A flow-based synthesis of Imatinib: the API of Gleevec

(2010) Mark D. Hopkin et al.   CHEMICAL COMMUNICATIONS

Non-ATP Competitive Protein Kinase Inhibitors

(2010) L. Garuti et al.   CURRENT MEDICINAL CHEMISTRY

The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer

(2010) Leyre Brizuela et al.   FASEB JOURNAL

Protein Kinase−Inhibitor Database: Structural Variability of and Inhibitor Interactions with the Protein Kinase P-Loop

(2010) Ronak Y. Patel et al.   JOURNAL OF PROTEOME RESEARCH

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

(2010) Kenichi Suda et al.   Journal of Thoracic Oncology

The (un)targeted cancer kinome

(2010) Oleg Fedorov et al.   Nature Chemical Biology

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

(2010) Brian B. Hasinoff   TOXICOLOGY AND APPLIED PHARMACOLOGY

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics

(2009) Lindsay O. Kirkland et al.   BIOCHEMICAL PHARMACOLOGY

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

(2009) Özgür Sahin et al.   BMC Systems Biology

Quercetin Inhibit Human SW480 Colon Cancer Growth in Association with Inhibition of Cyclin D1and Survivin Expression through Wnt/β-Catenin Signaling Pathway

(2009) Bao-En Shan et al.   CANCER INVESTIGATION

Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells

(2009) Cristina P.R. Xavier et al.   CANCER LETTERS

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer Cells

(2009) S. A. Milligan et al.   CLINICAL CANCER RESEARCH

Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design

(2009) Seungil Han et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

(2009) Fabio Zuccotto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Akt is a direct target for myricetin to inhibit cell transformation

(2009) Takuma Kumamoto et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

(2009) Monica Red Brewer et al.   MOLECULAR CELL

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

(2008) Richard M. Angell et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

(2008) Antonella Converso et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells

(2008) M. Narasimhan et al.   CANCER RESEARCH

Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study

(2008) P. Kaur et al.   CARCINOGENESIS

Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation

(2008) Panagis Filippakopoulos et al.   CELL

Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment

(2008) P. Sharma et al.   CURRENT CANCER DRUG TARGETS

Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy

(2008) Yong Lin et al.   CURRENT CANCER DRUG TARGETS

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

(2008) S. Shukla et al.   DRUG METABOLISM AND DISPOSITION

Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States

(2008) Irina Kufareva et al.   JOURNAL OF MEDICINAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Do molecularly targeted agents in oncology have reduced attrition rates?

(2008) Ian Walker et al.   NATURE REVIEWS DRUG DISCOVERY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemopreventive Potential of Resveratrol in Mouse Skin Tumors Through Regulation of Mitochondrial and PI3K/AKT Signaling Pathways

(2008) Preeti Roy et al.   PHARMACEUTICAL RESEARCH

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA